FDA Fights Problems With Pre-ANDA Meeting Requests
More Pre-ANDA Meeting Requests Are Being Denied
More meeting requests are being denied because the sponsor's pre-meeting package was incomplete, the agency said.
You may also be interested in...
Averages likely will increase as more of the cohort is approved, however.
US FDA met more biosimilar user fee program meeting performance goals in FY 2018 compared to prior year but still fell short in scheduling for three of five types of meetings. Office of New Drugs reorganization, once completed, should address some logistical scheduling issues.
US agency says it is implementing generic drug user fee program as outlined in commitment letter and any changes should be discussed at negotiations for the 2022 renewal.